GlassScriptPhysician profile
Ligeng Tian
NPI 1326379249
$3,805.17
in general payments reported to CMS, 2019-2025
18 companies · $412 in 2025
The $412 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $181 · 2021: $137 · 2022: $1,423 · 2023: $348 · 2024: $1,048 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862 · Long Term Medical Supply Or Device Loan: $781 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150 · Education: $16.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.50 |
| Long Term Medical Supply Or Device Loan | $781.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
| Education | $16.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $1,500.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $922.34 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $357.72 | 2023-2024 | Imfinzi |
| Array Biopharma INC | $150.00 | 2025 | Braftovi, Lorbrena, Mektovi |
| Beone Medicines USA, INC. | $133.50 | 2025 | Tevimbra |
| Rigel Pharmaceuticals, INC. | $130.80 | 2024 | Tavalisse, Rezlidhia |
| Sobi, INC | $125.00 | 2025 | |
| Verastem, INC. | $118.39 | 2019 | |
| Kyowa Kirin, INC. | $111.85 | 2019 | |
| Abbvie INC. | $110.67 | 2023 | Venclexta |
| Eisai INC. | $50.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.76 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2024 | Onivyde |
| Lilly USA, LLC | $12.63 | 2019 | |
| Seagen INC. | $12.29 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Foundation Medicine, INC. | $11.26 | 2020 | |
| Pfizer INC. | $3.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ligeng Tian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.